Our Team

 Since September 2017, High Lantern Group (HLG) has served as the Secretariat for the Business Alliance Against Malaria (BAAM), the Private Sector Constituency to the Board of the RBM Partnership to End Malaria. In this role, HLG works with members to facilitate their interaction with the RBM Partnership to End Malaria’s as the Focal Point for the Private Sector’s Board seats, and within the malaria community at large. HLG also provides critical policy analysis, communications and coordination support to the alliance.

RBM Partnership to End Malaria Private Sector Constituency Board Representatives

SHERWIN CHARLES is the CEO and co-founder of Goodbye Malaria, an organization he co-founded Robbie Brozin (co-founder of Nando’s), Kim Lazarus and David Stern. Sherwin has been the CEO of Goodbye Malaria since 2015, when he left Nando’s a previous position with the Nando’s group. Sherwin has spent more than 15 years in the banking and financial services industry. As CEO of Goodbye Malaria, Sherwin developed a unique public private partnership between the MOSASWA (Mozambique, South Africa and Swaziland) governments and private sector. He has been involved in the development of sustainable financial solutions in Africa, including the development of a Malaria Bond. Sherwin is a regular guest speaker at global summits on innovative financing solutions or malaria eradication.

CAROLINE DESROUSSEAUX is Vestergaard’s Director of Sales for Public Health products. She has held positions in business and partnership development, account management, and contracting in both the private sector and the non-for-profit sector. She came to Vestergaard from Management Sciences for Health, an international NGO tackling global health challenges through health systems strengthening interventions and headquartered in Boston, Massachusetts. She is a French national and holds a Master’s degree from Sciences-Po’s School of management in Paris and a Master’s degree in entrepreneurship and small business management from the University of Paris Descartes.

RBM Partnership to End Malaria Private Sector Constituency Board Alternatve Representatives

JULIANA RICHARDSON directs the external engagement and partnership strategies for Novartis Global Health Programs, including Sickle Cell Disease, Malaria, Leprosy, and Chagas disease. In her role, she also helps to coordinate external engagements for Novartis Global Health & Sustainability, including senior-level government interactions and Novartis’s presence at key global health summits and forums. As part of the Novartis Africa SCD Program, Juliana builds multisectoral partnerships with like minded entities to support comprehensive solutions for SCD through health system strengthening, advocacy and education initiatives.

Prior to her role at Novartis, Juliana worked for the US Government where she was integral to the forming of the World Coalition on SCD.

IAN BOULTON is Managing Director and Founder of TropMed Pharma Consulting (TMPC), a company specialising in working with public and private sector organisations working in the field of diseases of poverty (including malaria, TB, and dengue). Prior to setting up TMPC in 2008, he worked for nearly 35 years in the pharmaceutical industry across a wide range of disciplines. Twenty years of this were spent in Asia where he first experienced the impact of diseases of poverty and the fragility of the healthcare systems in many of those countries.

BAAM’s Secretariat

MARIO OTTIGLIO is a Managing Director of High Lantern Group (HLG) and head of the Geneva office. He brings over a decade of leadership at global health organizations – spanning the public and private sectors. Before founding HLG in Europe, Mario served as the Director of Public Affairs, Communications & Global Health Policy at the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). In this role, he acted as a spokesperson for the global R&D biopharmaceutical industry, promoting active, cross-sector dialogue with key stakeholders, often involved with high-profile media, and authored several thought pieces.

CASSIE DORMOND is a Director at HLG. She has experience in corporate social responsibility, partnership building and management, and global affairs. Before HLG, Cassie served as the private sector liaison to the Board of the Global Fund to Fight HIV, Tuberculosis, and Malaria where she realized engagement opportunities for business leaders and corporations to partner with the Global Fund. Cassie also worked as a US healthcare sector consultant with The Advisory Board Company and as an advisor to the CEO at a global health charity.

SAGAR SANE is an Associate Director at High Lantern Group’s Asheville, NC office. Since joining the firm in 2017, Sagar’s healthcare work has centered around infectious diseases, aging and longevity, Alzheimer’s and dementia, skin health, antimicrobial resistance, and digital transformation. Sagar specializes in market, policy, and stakeholder research and is particularly interested in health advocacy campaigns and the role that private sector organizations can play in tackling emerging global challenges. Prior to joining HLG, Sagar spent 5 years managing political campaigns in North Carolina.

EMMA EDNEY is an associate at the New York office, contributing to projects incorporating patient advocacy into healthcare systems and writing targeted communications that shape the mental health landscape. She supports client engagement and policy development across Healthcare, Pharma, and Technology sectors. Prior to HLG, Emma served as a political research assistant on electoral campaigns, a New York City Council canvasser, and scholarship fundraiser.